Spots Global Cancer Trial Database for Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma
Official Title: A Phase II Window-of-opportunity Study of Preoperative Therapy With Pazopanib (Votrient®) in High-risk Soft Tissue Sarcoma
Study ID: NCT01543802
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to examine if a short-term treatment with pazopanib, an oral drug inhibiting the growth of blood vessel, can reduce the metabolism of soft-tissue sarcomas and thus facilitate their resection when given prior to surgery. Moreover, the study assesses the prognostic and predictive value of several new biomarkers (endothelial progenitor cells, soluble vascular epithelial growth factor),
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Klinikum Frankfurt-Höchst, Frankfurt am Main, , Germany
German Cancer Research Center, Medical PET Group - Biological Imaging, Heidelberg, , Germany
University Hospital Heidelberg / National Centre for Tumor Diseases, Heidelberg, , Germany
University Hospital Mannheim, Dpt. of Surgery, Mannheim, , Germany
Contact Details
Name: Peter Hohenberger, MD
Affiliation: University Hospital Mannheim, Department of Surgery
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
